Edwards Lifesciences (EW) Stock Price, News & Analysis

Company Overview

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement. Its products are used by hospitals and heart specialists to treat conditions such as aortic stenosis and other heart valve disorders, providing alternatives to traditional open-heart surgery for certain patients.

Edwards Lifesciences serves healthcare providers and patients in the United States and international markets across Europe, Asia-Pacific, and other regions. The company is headquartered in Irvine, California, and is led by President and Chief Executive Officer Bernard Zovighian.

Key Stats

• Today's Range: $85.07 to $86.77
• 50-Day Range: $84.18 to $93.59
• 52-Week Range: $72.40 to $96.29
• Volume: 3.64 million shs
• Average Volume: 3.79 million shs
• Market Capitalization: $49.09 billion
• P/E Ratio: 30.74
• Dividend Yield: N/A
• Price Target: $100.27
• Consensus Rating: Moderate Buy

Edwards Lifesciences Stock Analysis - MarketRank™

Edwards Lifesciences scored higher than 85% of companies evaluated by MarketBeat, and ranked 135th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Edwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 16 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

Edwards Lifesciences has a consensus price target of $100.27, representing about 17.6% upside from its current price of $85.26.

Amount of Analyst Coverage

Edwards Lifesciences has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 13.00%

Earnings Growth

Earnings for Edwards Lifesciences are expected to grow by 13.00% in the coming year, from $3.00 to $3.39 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Edwards Lifesciences is 30.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of Edwards Lifesciences is 30.74, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.97.

Price to Earnings Growth Ratio

Edwards Lifesciences has a PEG Ratio of 2.26. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Edwards Lifesciences has a P/B Ratio of 4.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.66% of the float of Edwards Lifesciences has been sold short.

Short Interest Ratio / Days to Cover

Edwards Lifesciences has a short interest ratio ("days to cover") of 2.46, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Edwards Lifesciences has recently increased by 4.96%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Edwards Lifesciences does not currently pay a dividend.

Dividend Growth

Edwards Lifesciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.53

News Sentiment

Edwards Lifesciences has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Edwards Lifesciences this week, compared to 7 articles on an average week.

Search Interest

12 people have searched for EW on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

6 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $451,596.00 in company stock.

Percentage Held by Insiders

0.31% of the stock of Edwards Lifesciences is held by insiders.

Percentage Held by Institutions

79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/23/2026
• Today: 10/13/2026
• Investor update: 11/02/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:EW
• CIK: 1099800
• Web: www.edwards.com
• Phone: (949) 250-2500
• Fax: 949-250-2525
• Employees: 16,000
• Year Founded: 1958

Price Target and Rating

• Average Price Target for Edwards Lifesciences: $100.27
• High Price Target: $110.00
• Low Price Target: $85.00
• Potential Upside/Downside: +17.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 22 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.74
• Trailing P/E Ratio: 30.74
• Forward P/E Ratio: 28.42
• P/E Growth: 2.26
• Net Income: $1.07 billion
• Net Margins: 15.43%
• Pretax Margin: 21.77%
• Return on Equity: 15.68%
• Return on Assets: 12.05%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 4.52
• Quick Ratio: 3.77

Sales & Book Value

• Annual Sales: $6.07 billion
• Price / Sales: 8.09
• Cash Flow: $2.81 per share
• Price / Cash Flow: 30.30
• Book Value: $17.81 per share
• Price / Book: 4.79

Miscellaneous

• Outstanding Shares: 575,800,000
• Free Float: 574,015,000
• Market Cap: $49.09 billion
• Optionable: Optionable
• Beta: 0.87